Contineum Therapeutics Target of Unusually High Options Trading (NASDAQ:CTNM)

Contineum Therapeutics, Inc. (NASDAQ:CTNM) was the target of some unusual options trading on Tuesday. Traders acquired 10,034 call options on the company. This is an increase of approximately 4,420% compared to the average daily volume of 222 call options.

Key Headlines Impacting Contineum Therapeutics

Here are the key news stories impacting Contineum Therapeutics this week:

• Positive Sentiment: JonesTrading maintained a “buy” rating while lowering its price target from $26 to $24, implying substantial upside from recent levels. JonesTrading price target update
• Positive Sentiment: Investors purchased 10,034 CTNM call options, roughly 44 times the typical volume of 222 contracts. The unusually high call activity may signal speculative bullish interest, although options trading does not guarantee a sustained recovery.
• Positive Sentiment: Robert W. Baird retained an “outperform” rating and set a $19 price target, despite reducing its target from $20, indicating that the firm still sees meaningful value in Contineum’s broader pipeline.
• Negative Sentiment: The company reported that MOONLIGHT-1 did not achieve its primary endpoint, which measured the change in MADRS depression scores at Day 5 versus placebo. The disappointing result weakens the near-term investment case and may increase uncertainty around the drug candidate’s development path. Contineum Therapeutics Phase 2 results
• Negative Sentiment: Reports tied the stock’s decline to the failed major depressive disorder trial, suggesting investors are repricing the company’s clinical and commercial prospects following the readout. MOONLIGHT-1 trial misses primary endpoint

Analyst Ratings Changes

CTNM has been the topic of a number of recent analyst reports. JonesTrading lowered their target price on shares of Contineum Therapeutics from $26.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday. Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Robert W. Baird dropped their price target on Contineum Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday. Royal Bank Of Canada upped their target price on Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.80.

Institutional Investors Weigh In On Contineum Therapeutics

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada grew its stake in Contineum Therapeutics by 73.5% in the first quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after purchasing an additional 2,454 shares during the last quarter. Cannon Global Investment Management LLC acquired a new stake in Contineum Therapeutics during the 1st quarter worth about $170,000. Independent Financial Group LLC purchased a new stake in Contineum Therapeutics in the first quarter valued at approximately $353,000. Seven Fleet Capital Management LP purchased a new position in shares of Contineum Therapeutics during the first quarter worth $353,000. Finally, Bank of America Corp DE boosted its stake in shares of Contineum Therapeutics by 411.9% in the first quarter. Bank of America Corp DE now owns 47,449 shares of the company’s stock worth $620,000 after buying an additional 38,180 shares during the last quarter.

Contineum Therapeutics Price Performance

Shares of NASDAQ:CTNM traded down $1.52 during trading on Tuesday, hitting $13.30. 339,944 shares of the company’s stock were exchanged, compared to its average volume of 325,277. The company has a market cap of $500.46 million, a price-to-earnings ratio of -7.69 and a beta of 0.75. Contineum Therapeutics has a 52-week low of $8.60 and a 52-week high of $17.78. The business’s 50-day simple moving average is $15.36 and its 200 day simple moving average is $14.05.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. On average, sell-side analysts anticipate that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

About Contineum Therapeutics

Contineum Therapeutics, formerly known as Pipeline Therapeutics, is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for diseases of the central nervous system. The company’s research is aimed at promoting remyelination and neurorepair, processes that may restore damaged nerve function rather than solely managing disease symptoms.

Contineum’s lead programs include PIPE-307, an oral, brain-penetrant therapy designed to promote remyelination through selective inhibition of the M1 muscarinic receptor, and PIPE-791, an oral antagonist of the lysophosphatidic acid receptor 1.